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Infection by parasitic nematodes is widespread in the developing world causing extensive morbidity
and mortality. Furthermore, infection of animals is a global problem, with a substantial impact on
food production. Here we identify small molecule inhibitors of a nematode-specific metalloprotease,
DPY-31, using both known metalloprotease inhibitors and virtual screening. This strategy successfully
identified several lM inhibitors of DPY-31 from both the human filarial nematode Brugia malayi, and
the parasitic gastrointestinal nematode of sheep Teladorsagia circumcincta. Further studies using both
free living and parasitic nematodes show that these inhibitors elicit the severe body morphology
defect ‘Dumpy’ (Dpy; shorter and fatter), a predominantly non-viable phenotype consistent with
mutants lacking the DPY-31 gene. Taken together, these results represent a start point in developing
DPY-31 inhibition as a totally novel mechanism for treating infection by parasitic nematodes in
humans and animals.
 2015 Elsevier Ltd. All rights reserved.More than 1 billion people, predominantly in the developing
world, are infected by parasitic nematodes (helminths). The pri-
mary strategy for eliminating these infections is preventive
chemotherapy by mass anthelmintic drug administration, an
approach that will select for drug resistance.1 Furthermore,
helminth infection also represents a significant global burden to
livestock.2 Resistance to anthelmintic drugs is increasing in
gastrointestinal (GI) parasites of livestock, causing concern that
this will also occur in human parasites. This increased resistance
coupled with the limited availability of new drugs and absence
of vaccines means that the identification of new potential targets
for drug intervention is critical.3
The life cycle of all nematodes requires cyclical repetitive shed-
ding of the organism’s protective cuticle and concomitant genera-
tion of a new cuticle at several points during maturation. This
molting process involves a specific class of well-characterized
astacin metalloproteases.4 The zinc endopeptidase DPY-31 is a
nematode-specific member of this class that is essential for cuticle
formation.4d A mutant suppressor screen in Caenorhabditis elegans
identified the target of DPY-31 to be the cuticle collagen SQT-3,and specified the C-terminal cleavage domain of this crucial
structural protein where DPY-31 acts.5 Critically, without the
ability to molt, a nematode will fail to develop and ultimately
die prematurely.
Here we describe the identification of small molecule inhibitors
of DPY-31 employing two different approaches: use of known met-
alloprotease inhibitors and virtual screening. These compounds
were screened for activity against recombinantly expressed DPY-
31 from both the human filarial nematode Brugia malayi, and the
parasitic GI nematode of sheep Teladorsagia circumcincta. Active
compounds were then tested against both free living and parasitic
nematodes themselves.
Seven known zinc protease inhibitors were included for testing
(Fig. 1). The phosphinic pseudopeptide 1 used in the virtual
screening described below is a mid-lM inhibitor of crayfish asta-
cin and is studied here in the context of the nematode astacin
DPY-31.6 Furthermore, the antibiotic and CD13/aminopeptidase
N inhibitor actinonin (2),7 and the broad-spectrum matrix
metalloprotease inhibitor marimastat (3),8 were examined. Four
non-peptidic inhibitors of human procollagen C-proteinase (4–7)
developed by Pfizer were also screened for in vitro activity against
DPY-31.9
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Figure 1. Known metalloprotease inhibitors screened against DPY-31.
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Figure 2. Novel tripeptide hydroxamic acids screened against DPY-31.
2 D. J. France et al. / Bioorg. Med. Chem. Lett. xxx (2015) xxx–xxxFinally, two tripeptide hydroxamic acids were prepared bearing
two different carbamates on the N-terminus (Fig. 2). The hydrox-
amic acids were installed by CDI coupling of O-TMS-hydroxy-
lamine with corresponding tripeptides, followed by hydrolysis.10
These structures were selected on the basis of studies showing
the importance of a P1 aryl methyl group and P3 proline for bind-
ing to homologous crayfish astacin.6 It is also noteworthy that
these substrate analogs are complementary to the transition state
analog phosphinic pseudopeptide 1.
A combination of ligand-based and structure-based methods
were used for the in silico prediction of DPY-31 binding.10
Ligand-based screening was carried out by comparing a custom
virtual library to molecules in the PDB that bind to enzymes
homologous to DPY-31.10 Briefly, the custom virtual library was
generated by merging the screening compound stock lists of sev-
eral suppliers. The virtual library was then filtered according to
the Oprea lead-like rules.11 This left 1,137,587 molecules, whichPlease cite this article in press as: France, D. J.; et al. Bioorg. Med. Chemformed the base library. A multiconformer version of this base
library was produced using Multiconf-DOCK;12 resulting in a vir-
tual library containing a total of 4,840,093 conformers. A search
for compounds that contained one or more zinc-coordinating func-
tional groups (hydroxamates, mercaptosulfides, phosphinic acids,
sulfodiimines) was carried out using Sieve. 100 random conforma-
tions for each of the matches found were generated using
Multiconf-DOCK. The programs UFSRAT and ROCS were used to
search the custom virtual library for molecules with different types
of similarity to the known ligands.10
As DPY-31 has not been crystallized, structure-based virtual
screening was carried out using a 3D homology model of
C. elegans DPY-31 constructed using Modeller13 (Fig. 3A–C), and
the structure of crayfish astacin in complex with phosphinic pseu-
dopeptide transition state analog 1 (Fig. 1, PDB 1QJI).6 This
resulted in a model with Modeller objective function of 1342.4
(Fig. 3D).
The rigid-body docking program LIDAEUS was used to dock the
conformer virtual library into the substrate binding groove of
the DPY-31 model. The results were ranked and merged with the
results from the ligand-based methods described above. These
unique molecules were then docked into DPY-31 using Vina. The
top compounds were then docked using Autodock and compounds
whose predicted binding modes differed between the programs
were discarded.14 Predicted binding poses were also scored using
DrugScore 1.2.15 A final ranked list was prepared via a rank-by-
rank consensus scheme,16 taking the Vina, Autodock, X-Score and
DrugScore scores into account. The top 200 virtual hits were clus-
tered according to similarity (Tanimoto < 0.7) and one compound
from each cluster was selected for purchase (46 compounds). A
further 28 compounds were selected for purchase as structural
analogs of the molecules that were identified using the virtual
screening techniques described above.
In total, 104 compounds were screened against recombinant
DPY-31 from both the human parasite B. malayi as well as the
sheep GI parasite T. circumcincta using an absorbance assay.4i,10
Data for four of the most active compounds are given in Table 1.
In keeping with the high level of sequence homology of DPY-31
across species,4g,i these inhibitors displayed broadly similar
efficacy between the two species. Surprisingly, the phosphinic
pseudopeptide 1 was inactive in this in vitro assay
(IC50 > 500 lM). This may be due to the extremely slow binding
kinetics of these inhibitors.17 Furthermore, shorter dipeptide
hydroxamic acids (cf. 8 and 9) were inactive in this assay.
Having successfully demonstrated small molecule inhibition of
isolated DPY-31, we selected tripeptide hydroxamic acids 8 and 9
for phenotypic screening. These compounds were tested against
three strains: free-living wild-type C. elegans N2, the T. circumcincta
dpy-31 transgenically-rescued C. elegans dpy-31mutant TP224, and
parasitic T. circumcincta (Fig. 4). Phenotypes were evaluated in 96
well plate format over the course of 3 days using concentrations
ranging from 50 lM to 2 mM. Both compounds were able to induce
the Dpy phenotype that is consistent with loss of function of
DPY-31.4d The similarity of these effects between wild-type
C. elegans, the mutant strain, and T. circumcincta reinforces the
conserved nature of this metalloprotease.
In conclusion, using a combination of in silico and experimental
methods, we have identified small molecule inhibitors of the nema-
tode-specific astacinmetalloprotease DPY-31, which is essential for
cuticle collagen biogenesis. These compounds are active against
recombinant DPY-31 from both human and livestock nematode
parasites. Furthermore, we have shown that these compounds
can elicit the specific body morphology defect associated with defi-
ciency of this essential protein in both free-living and parasitic
nematodes. In C. elegans, these compounds replicate the phenotype. Lett. (2015), http://dx.doi.org/10.1016/j.bmcl.2015.10.077
Figure 3. 3D homology models of C. elegans DPY-31 alone, and crayfish astacin in complex with a phosphinic pseudopeptide transition state analog. (A) 3D homology model
of C. elegans DPY-31, with (B) and (C) showing a closer view of the catalytic zinc-binding site, (D) 3D homology model of crayfish astacin in complex with phosphinic
pseudopeptide transition state analog 1.
Table 1
Inhibition of recombinant DPY-31 from B. malayi and T. circumcincta (±standard error)
Compound pIC50 rDPY-31
B. malayi T. circumcincta
3 3.7 ± 0.2 4.1 ± 0.5
6 4.7 ± 0.3 4.4 ± 0.3
8 4.1 ± 0.4 4.6 ± 0.3
9 4.6 ± 0.4 4.5 ± 0.2
D. J. France et al. / Bioorg. Med. Chem. Lett. xxx (2015) xxx–xxx 3associated with mutation of the dpy-31 metalloprotease encoding
gene.4d,g These results represent a first step toward validation of
DPY-31 as a totally novel target for drug intervention in the
treatment and control of parasitic nematodes of medical and
veterinary significance. Future SAR work is expected to enhance
potency while ensuring selectivity for DPY-31.Figure 4. (a) WT L1 C. elegans (N2). (b) Dpy phenotype in L1 C. elegans (N2) with
50 lM 8. (c) WT L1 transgenic rescue strain TP224. (d) Dpy L1 phenotype in TP224
with 100 lM 8. (e) WT T. circumcincta L3. (f) Dpy phenotype in T. circumcincta L3
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